Liposome-Derived Nanosystems for the Treatment of Behavioral and Neurodegenerative Diseases: The Promise of Niosomes, Transfersomes, and Ethosomes for Increased Brain Drug Bioavailability DOI Creative Commons
Patrícia C. Pires, Ana Cláudia Paiva‐Santos, Francisco Veiga

et al.

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(10), P. 1424 - 1424

Published: Oct. 8, 2023

Psychiatric and neurodegenerative disorders are amongst the most prevalent debilitating diseases, but current treatments either have low success rates, greatly due to permeability of blood–brain barrier, and/or connected severe side effects. Hence, new strategies extremely important, here is where liposome-derived nanosystems come in. Niosomes, transfersomes, ethosomes nanometric vesicular structures that allow drug encapsulation, protecting them from degradation, increasing their solubility, permeability, brain targeting, bioavailability. This review highlighted great potential these for treatment Alzheimer’s disease, Parkinson’s schizophrenia, bipolar disorder, anxiety, depression. Studies regarding encapsulation synthetic natural-derived molecules in systems, intravenous, oral, transdermal, or intranasal administration, led an increased bioavailability when compared conventional pharmaceutical forms. Moreover, developed formulations proved neuroprotective, anti-inflammatory, antioxidant effects, including neurotransmitter level restoration oxidative status improvement, improved locomotor activity enhancement recognition working memories animal models. albeit being relatively technologies, niosomes, already proven increase psychoactive drugs, leading effectiveness decreased showing promise as future therapeutics.

Language: Английский

Major depressive disorder DOI
Wolfgang Marx, Brenda W.J.H. Penninx, Marco Solmi

et al.

Nature Reviews Disease Primers, Journal Year: 2023, Volume and Issue: 9(1)

Published: Aug. 24, 2023

Language: Английский

Citations

225
A Gpr35-tuned gut microbe-brain metabolic axis regulates depressive-like behavior DOI Creative Commons

Lingsha Cheng,

Haoqian Wu, Xiaoying Cai

et al.

Cell Host & Microbe, Journal Year: 2024, Volume and Issue: 32(2), P. 227 - 243.e6

Published: Jan. 9, 2024

Language: Английский

Citations

36
Management of Depression in Adults DOI
Gregory E. Simon,

Nathalie Moise,

David C. Mohr

et al.

JAMA, Journal Year: 2024, Volume and Issue: 332(2), P. 141 - 141

Published: June 10, 2024

Importance Approximately 9% of US adults experience major depression each year, with a lifetime prevalence approximately 17% for men and 30% women. Observations Major is defined by depressed mood, loss interest in activities, associated psychological somatic symptoms lasting at least 2 weeks. Evaluation should include structured assessment severity as well risk self-harm, suspected bipolar disorder, psychotic symptoms, substance use, co-occurring anxiety disorder. First-line treatments specific psychotherapies antidepressant medications. A network meta-analysis randomized clinical trials reported cognitive therapy, behavioral activation, problem-solving interpersonal brief psychodynamic mindfulness-based psychotherapy all had medium-sized effects symptom improvement over usual care without (standardized mean difference [SMD] ranging from 0.50 [95% CI, 0.20-0.81] to 0.73 0.52-0.95]). 21 medications small- placebo (SMD 0.23 0.19-0.28] fluoxetine 0.48 0.41-0.55] amitriptyline). Psychotherapy combined medication may be preferred, especially more severe or chronic depression. greater treatment than alone (SMD, 0.30 0.14-0.45]) 0.33 0.20-0.47]). When initial not effective, second-line includes changing medication, adding second antidepressant, augmenting nonantidepressant which have equal likelihood success based on meta-analysis. Collaborative programs, including systematic follow-up outcome assessment, improve effectiveness, 1 reporting significantly compared 0.42 0.23-0.61]). Conclusions Relevance Effective first-line forms 20 Close monitoring improves the success.

Language: Английский

Citations

33
Gut microbiota-derived short-chain fatty acids and depression: deep insight into biological mechanisms and potential applications DOI Creative Commons

Junzhe Cheng,

Hongkun Hu, Yumeng Ju

et al.

General Psychiatry, Journal Year: 2024, Volume and Issue: 37(1), P. e101374 - e101374

Published: Feb. 1, 2024

The gut microbiota is a complex and dynamic ecosystem known as the ‘second brain’. Composing microbiota-gut-brain axis, its metabolites regulate central nervous system through neural, endocrine immune pathways to ensure normal functioning of organism, tuning individuals’ health disease status. Short-chain fatty acids (SCFAs), main bioactive microbiota, are involved in several neuropsychiatric disorders, including depression. SCFAs have essential effects on each component axis In present review, roles major (acetate, propionate butyrate) pathophysiology depression summarised with respect chronic cerebral hypoperfusion, neuroinflammation, host epigenome neuroendocrine alterations. Concluding remarks biological mechanisms related will hopefully address clinical value microbiota-related treatments for

Language: Английский

Citations

29
Association between Weight-Adjusted Waist Index and depressive symptoms: A nationally representative cross-sectional study from NHANES 2005 to 2018 DOI
Hangyu Liu,

Jin Zhi,

Chuzhao Zhang

et al.

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: 350, P. 49 - 57

Published: Jan. 13, 2024

Language: Английский

Citations

28
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics? DOI Creative Commons
Kenji Hashimoto

European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 27, 2024

The growing interest in the rapid and sustained antidepressant effects of dissociative anesthetic ketamine classic psychedelics, such as psilocybin, is remarkable. However, both psychedelics are known to induce acute mystical experiences; can cause symptoms out-of-body experience, while typically bring about hallucinogenic experiences, like a profound sense unity with universe or nature. role these experiences enhancing outcomes for patients depression currently an area ongoing investigation debate. Clinical studies have shown that following administration (S)-ketamine (esketamine) not directly linked their properties. In contrast, potential (R)-ketamine (arketamine), thought lack side effects, has yet be conclusively proven large-scale clinical trials. Moreover, although activation serotonin 5-HT

Language: Английский

Citations

28
Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial DOI Creative Commons
Shuo Wang,

Chun-Mei Deng,

Yuan Zeng

et al.

BMJ, Journal Year: 2024, Volume and Issue: unknown, P. e078218 - e078218

Published: April 10, 2024

Abstract Objective To determine whether a single low dose of esketamine administered after childbirth reduces postpartum depression in mothers with prenatal depression. Design Randomised, double blind, placebo controlled trial two parallel arms. Setting Five tertiary care hospitals China, 19 June 2020 to 3 August 2022. Participants 364 aged ≥18 years who had at least mild as indicated by Edinburgh postnatal scale scores ≥10 (range 0-30, higher indicating worse depression) and were admitted hospital for delivery. Interventions randomly assigned 1:1 receive either 0.2 mg/kg or infused intravenously over 40 minutes once the umbilical cord been clamped. Main outcome measures The primary was prevalence major depressive episode 42 days post partum, diagnosed using mini-international neuropsychiatric interview. Secondary outcomes included score seven partum 17 item Hamilton rating 0-52, depression). Adverse events monitored until 24 hours childbirth. Results A total (mean age 31.8 (standard deviation 4.1) years) enrolled randomised. At observed 6.7% (12/180) participants group compared 25.4% (46/181) (relative risk 0.26, 95% confidence interval (CI) 0.14 0.48; P<0.001). lower (median difference −3, CI −4 −2; P<0.001) (−3, also (−4, −6 −3; overall incidence adverse (45.1% (82/182) v 22.0% (40/182); P<0.001); however, symptoms lasted less than day none required drug treatment. Conclusions For depression, decreases episodes about three quarters. Neuropsychiatric more frequent but transient did not require intervention. Trial registration ClinicalTrials.gov NCT04414943 .

Language: Английский

Citations

24
PI3K/AKT signaling pathway: Molecular mechanisms and therapeutic potential in depression DOI Creative Commons
Ningning Guo, Xin Wang,

Muran Xu

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: 206, P. 107300 - 107300

Published: July 9, 2024

Depression is a serious global mental disorder. Numerous studies have found that depression may be closely related to decreased neurogenesis, neuroinflammation, neurotransmitter imbalance, and synaptic plasticity dysfunction. The pathogenesis of complex involves multiple signal transduction pathways molecular changes. PI3K/AKT pathway an essential signaling in neurons, which widely expressed emotion-related regions the brain. Therefore, play moderating role mood disorders. However, mechanism not been fully described. This review systematically summarized discussed its potential treatment depression. will help development antidepressants.

Language: Английский

Citations

23
Innovation at the Intersection: Emerging Translational Research in Neurology and Psychiatry DOI Creative Commons
Masaru Tanaka, Simone Battaglia, Lydia Giménez‐Llort

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(10), P. 790 - 790

Published: May 7, 2024

Translational research in neurological and psychiatric diseases is a rapidly advancing field that promises to redefine our approach these complex conditions [...]

Language: Английский

Citations

19
Innovation at the Intersection: Emerging Translational Research in Neurology and Psychiatry DOI Open Access
Masaru Tanaka, Simone Battaglia, Lydia Giménez‐Llort

et al.

Published: April 17, 2024

The editorial explores the realm of emerging translational research in neurology and psychiatry, providing insights into various subjects, including neurodegenerative disorders innovative therapeutic methods. main objective is to study neurological psychiatric disorders, such as Alzheimer's disease, with a particular emphasis on techniques for neural regeneration repair. highlights importance taking comprehensive approach studying treating complex conditions. This involves thoroughly reviewing papers causes, development, biomarkers, treatment options these emphasizes necessity using multidisciplinary integrative methods gain deeper understanding improve development an animal model recurrent primary dysmenorrhea showcases employed investigation gynecological illustrating capacity connect fundamental scientific knowledge practical medical applications. cooperative endeavors researchers clinicians emphasized this lay foundation revolutionary advancements that hold potential enhance outcomes individuals afflicted globally.

Language: Английский

Citations

17